Abstract
Personalized medicine driven by diagnostics has potential to improve patient outcomes and save costs for payers. However, a significant number of diagnostics are unable to receive reimbursement coverage for market access. The objective of this analysis was to understand the evidence requirements for diagnostics based on review of NICE Health Technology Assessment (HTA) reports.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
